Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.

Oncotarget - 20 Jul 2015

Ghosh Arindam P, Marshall Christopher B, Coric Tatjana, Shim Eun-Hee, Kirkman Richard, Ballestas Mary E, Ikura Mitsuhiko, Bjornsti Mary-Ann, Sudarshan Sunil

Abstract excerpt

Aberrations in the mTOR (mechanistic target of rapamycin) axis are frequently reported in cancer. Using publicly available tumor genome sequencing data, we identified several point mutations in MTOR and its upstream regulator RHEB (Ras homolog enriched in brain) in patients with clear cell renal cell carcinoma (ccRCC), the most common histology of kidney cancer. Interestingly, we found a prominent cluster of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to GTPase-Activating Proteins
Share to Mechanistic Target of Rapamycin Complex 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mechanistic Target of Rapamycin Complex 2

Share to Monomeric GTP-Binding Proteins

Share to Multiprotein Complexes

Share to Neuropeptides

Share to Sirolimus

Share to Tuberous Sclerosis Complex 2 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 26255626
DOI: 10.18632/oncotarget.4963
PMCID: PMC4627224

Genes

RHEB
MTOR
TSC2
ATM
DEPTOR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.PMID 26255626Read ↗

Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.Semantic proximity Read ↗

A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.Semantic proximity Read ↗

Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

Activating mTOR Mutations Are Detrimental in Nutrient-Poor Conditions.Semantic proximity Read ↗

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.Semantic proximity Read ↗

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma.Semantic proximity Read ↗

Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.Semantic proximity Read ↗

Interplay Between pVHL and mTORC1 Pathways in Clear-Cell Renal Cell CarcinomaSemantic proximity Read ↗

VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinomaSemantic proximity Read ↗

PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinomaSemantic proximity Read ↗

The Spectrum of Renal “TFEopathies”: Flipping the mTOR Switch in Renal TumorigenesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.